RLYB

Rallybio Corp

Mar 30 • 04:00PM ET

8.04

-0.18 -2.19 %

Healthcare • Biotechnology • USA • NASD

Peers: CYTK BCRX AXSM ARDX ANAB XERS ADVM ASMB VTGN AKBA

Index	-	P/E	-	EPS (ttm)	-1.68	Insider Own	48.86%	Shs Outstand	5.28M	Perf Week	-11.75%
Market Cap	42.53M	Forward P/E	-	EPS next Y	-5.40	Insider Trans	-0.03%	Shs Float	2.71M	Perf Month	6.63%
Enterprise Value	-12.03M	PEG	-	EPS next Q	-1.24	Inst Own	22.29%	Short Float	29.44%	Perf Quarter	46.16%
Income	-8.98M	P/S	49.45	EPS this Y	83.08%	Inst Trans	8.12%	Short Ratio	6.11	Perf Half Y	82.73%
Sales	0.86M	P/B	0.73	EPS next Y	-200.00%	ROA	-13.77%	Short Interest	0.80M	Perf YTD	46.48%
Book/sh	10.97	P/C	0.78	EPS next 5Y	-	ROE	-15.01%	52W High	11.49 -30.03%	Perf Year	57.01%
Cash/sh	10.35	P/FCF	-	EPS past 3/5Y	54.34% 24.69%	ROIC	-15.47%	52W Low	1.76 356.61%	Perf 3Y	-82.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.28%	Volatility	6.10% 8.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-13.99	EPS Y/Y TTM	84.30%	Oper. Margin	-3457.34%	ATR (14)	0.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.50	Sales Y/Y TTM	34.91%	Profit Margin	-1046.39%	RSI (14)	45.24	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	14.50	EPS Q/Q	44.01%	SMA20	-15.48%	Beta	-1.13	Target Price	8.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	484.21%	SMA50	14.25%	Rel Volume	0.44	Prev Close	8.22
Employees	14	LT Debt/Eq	0.00	Earnings	Nov 06 BMO	SMA200	54.81%	Avg Volume	130.62K	Price	8.04
IPO	Jul 29, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	268.75% 217.84%	Trades		Volume	58,031	Change	-2.19%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-07-24	Downgrade	Jefferies	Buy → Hold	$7 → $1.50
Apr-17-23	Initiated	H.C. Wainwright	Buy	$18
Apr-10-23	Initiated	Wedbush	Outperform	$17
Dec-09-22	Initiated	JP Morgan	Overweight	$21
Feb-22-22	Initiated	JMP Securities	Mkt Outperform	$32
Aug-23-21	Initiated	Jefferies	Buy	$20
Aug-23-21	Initiated	Evercore ISI	Outperform	$40
Aug-23-21	Initiated	Cowen	Outperform

Mar-06-26 11:15AM	Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? (PR Newswire)
Mar-03-26 07:20AM	Rallybio to acquire Candid Therapeutics (Pharmaceutical Business Review)
Mar-02-26 03:56PM	Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? (PR Newswire) +45.49%
10:51AM	Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism (Benzinga) +45.49%
08:00AM	Rallybio Corporation and Candid Therapeutics Announce Merger Agreement (Business Wire) +45.49%
06:05AM	Loading…
06:05AM	Candid, in a reverse merger with RallyBio, to go public (BioPharma Dive) +45.49%
Feb-17-26 10:46AM	Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 (Benzinga) -10.17%
08:00AM	Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement (Business Wire) -10.17%
Feb-04-26 10:05AM	Stock Splits Matter: Whats Coming Up This Month? (24/7 Wall St.) -8.12%
Feb-03-26 04:05PM	Rallybio Announces Reverse Stock Split of Common Stock (Business Wire)
Nov-06-25 08:00AM	Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Sep-25-25 08:00AM	Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study (Business Wire)
Sep-03-25 08:00AM	Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program (Business Wire)
Aug-07-25 08:00AM	Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Aug-05-25 06:30AM	Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
12:14AM	Loading…
Jul-21-25 12:14AM	Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia (Insider Monkey) +7.51%
Jul-09-25 11:56AM	RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program (Zacks) -12.71%
08:16AM	Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M (TipRanks) -12.71%
07:18AM	Rallybio sells REV102 programme to Recursion for up to $25m (Pharmaceutical Business Review) -12.71%
Jul-08-25 01:28PM	Here's Why Shares in Recursion Pharmaceuticals Surged Today (Motley Fool) +50.24%
08:00AM	Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia (GlobeNewswire) +50.24%
08:00AM	Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals (Business Wire) +50.24%
Jul-07-25 09:00AM	ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors (Business Wire)
Jun-12-25 08:00AM	Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study (Business Wire) -7.30%
May-08-25 08:00AM	Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Apr-29-25 08:00AM	Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference (Business Wire)
Apr-09-25 10:58AM	RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks (Zacks)
07:21AM	Rallybio drops drug for rare maternal disorder following Phase II fail (Clinical Trials Arena)
Apr-08-25 08:00AM	Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT (Business Wire) -41.16%
05:27AM	Rallybio discontinues lead drug for rare maternal disorder (BioPharma Dive) -41.16%
08:00AM	Loading…
Mar-13-25 08:00AM	Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Business Wire)
Feb-25-25 08:00AM	Rallybio to Present at the TD Cowen 45th Annual Health Care Conference (Business Wire) -6.30%
Feb-12-25 05:29AM	Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe (Clinical Trials Arena)
Feb-11-25 08:00AM	Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial (Business Wire)
Jan-10-25 08:00AM	Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 (Business Wire) -5.63%
Dec-10-24 08:00AM	Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting (Business Wire)
Dec-06-24 06:48AM	Rallybio price target lowered to $7 from $8 at JMP Securities (TipRanks)
Dec-02-24 08:00AM	Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 (Business Wire)
Nov-27-24 08:00AM	Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women (Business Wire)
Nov-26-24 08:00AM	Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference (Business Wire)
Nov-25-24 08:00AM	Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor (Business Wire)
Nov-22-24 07:01AM	Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women (Clinical Trials Arena)
Nov-21-24 08:00AM	Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 (Business Wire)
Nov-07-24 08:00AM	Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 02:59AM	Two former Alexion leaders fight through a tough market to maintain a rare disease biotech (Pharma Voice)
Oct-29-24 08:00AM	Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT (Business Wire)
Sep-30-24 08:00AM	Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting (Business Wire) +5.88%
Sep-23-24 08:00AM	Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting (Business Wire)
Sep-10-24 08:00AM	Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit (Business Wire)
Sep-09-24 05:15PM	Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree (Business Wire)
Aug-29-24 08:00AM	Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis (Business Wire)
Aug-27-24 08:00AM	Rallybio to Present at Upcoming Investor Conferences (Business Wire) +8.77%
Aug-14-24 12:00PM	Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-08-24 08:00AM	Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Jul-09-24 08:00AM	Rallybio to Present at the 2024 Jones Healthcare Seaside Summit (Business Wire)
Jun-17-24 08:00AM	Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations (Business Wire) -6.15%
May-31-24 07:00AM	3 Sorry Biotech Stocks to Sell in May While You Still Can (InvestorPlace) +5.03%
May-10-24 06:30AM	3 Biotech Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
May-09-24 01:54PM	RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024 (InvestorPlace)
10:14AM	Rallybio reins in preclinical R&D, while Monopar pivots to radiopharma to eke out cash (FierceBiotech.com)
08:00AM	Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
May-07-24 08:00AM	Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference (Business Wire)
Apr-17-24 04:01PM	FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting (Business Wire) -5.11%
Apr-12-24 10:23AM	RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up (Zacks) -26.17%
Apr-11-24 07:43AM	Why Is Rallybio (RLYB) Stock Up 93% Today? (InvestorPlace) +82.82%
Apr-10-24 04:01PM	Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (Business Wire)
01:01PM	J&J, Rallybio partner on drug development for rare fetal condition (BioPharma Dive)
Apr-01-24 10:05AM	Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting (Business Wire)
Mar-12-24 08:00AM	Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -8.70%
Feb-26-24 08:00AM	Rallybio to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire) +5.88%
Feb-06-24 09:46AM	Rallybio, with financial fuel levels falling, loses 45% of workforce to extend cash runway into 2026 (FierceBiotech.com) +24.00%
08:00AM	Rallybio Announces Portfolio Prioritization and Provides Corporate Update (Business Wire) +24.00%
Jan-04-24 08:00AM	Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024 (Business Wire)
Dec-20-23 08:00AM	Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire) -5.50%
Dec-09-23 12:00PM	Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting (Business Wire)
Nov-28-23 07:00AM	Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire)
Nov-09-23 08:00AM	Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Nov-08-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in November (Business Wire)
Nov-02-23 09:15AM	Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting (Business Wire)
Oct-03-23 08:00AM	Rallybio to Present at the JonesTrading 2023 Healthcare Summit (Business Wire)
Sep-03-23 12:00PM	Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire)
Aug-31-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in September (Business Wire)
Aug-08-23 08:00AM	Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Aug-02-23 08:00AM	Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference (Business Wire)
Jul-11-23 08:00AM	Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) (Business Wire)
Jun-29-23 07:00AM	Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023 (Business Wire)
Jun-24-23 03:30PM	Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire)
Jun-09-23 09:15AM	Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis (Business Wire)
Jun-01-23 08:00AM	Rallybio to Present at the Jefferies Healthcare Conference (Business Wire)
May-29-23 09:55AM	Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade (Zacks)
May-12-23 09:55AM	Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect? (Zacks)
May-09-23 08:00AM	Rallybio Reports First Quarter 2023 Financial Results (Business Wire)
May-08-23 08:00AM	Rallybio to Present at the JMP Securities 2023 Life Sciences Conference (Business Wire)
Apr-06-23 08:00AM	Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis (Business Wire)
Apr-03-23 08:00AM	Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) (Business Wire)
Mar-15-23 09:15AM	We're Not Very Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Rate (Simply Wall St.)
Mar-10-23 09:35AM	Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB) (Zacks)
Mar-06-23 02:49PM	Rallybio Pulls Plug On One Candidate After Highlighting Encouraging Data From Another Thrombocytopenia Program (Benzinga)
08:00AM	Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
07:30AM	Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire)

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lieber Jonathan I	Chief Financial Officer	Feb 23 '26	Sale	5.06	789	3,992	4,115	Feb 23 06:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLYB

Rallybio Corp

Upgrade your Finviz experience